<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0003-3170</journal-id>
<journal-title><![CDATA[Angiología]]></journal-title>
<abbrev-journal-title><![CDATA[Angiología]]></abbrev-journal-title>
<issn>0003-3170</issn>
<publisher>
<publisher-name><![CDATA[Arán Ediciones S.L.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0003-31702020000500002</article-id>
<article-id pub-id-type="doi">10.20960/angiologia.00105</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio prospectivo de la adecuación en la tromboprofilaxis en pacientes que ingresan en una unidad de corta estancia]]></article-title>
<article-title xml:lang="en"><![CDATA[A prospective study of the adequacy in the tromboprofilaxis in patients admitted in a short-stay unit]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera-Núñez]]></surname>
<given-names><![CDATA[María Angélica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tung-Chen]]></surname>
<given-names><![CDATA[Yale]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Huerta Álvarez]]></surname>
<given-names><![CDATA[María Consuelo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quintana Díaz]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Virto]]></surname>
<given-names><![CDATA[Ana María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres Santos-Olmo]]></surname>
<given-names><![CDATA[Rosario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario La Paz Servicio de Urgencias ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) Unidad de Farmacoepidemiología y Farmacovigilancia ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario La Paz Unidad de Cuidados Intensivos ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2020</year>
</pub-date>
<volume>72</volume>
<numero>5</numero>
<fpage>219</fpage>
<lpage>228</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0003-31702020000500002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0003-31702020000500002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0003-31702020000500002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: numerosos estudios avalan el uso de la tromboprofilaxis en pacientes con riesgo de enfermedad tromboembólica (ETV) que requieren de ingreso hospitalario. Existe escasa evidencia sobre las indicaciones de tromboprofilaxis en la población de pacientes agudos ingresados en una unidad de corta estancia.  Objetivos: estudiar el uso de la tromboprofilaxis en pacientes ingresados en una unidad de corta estancia del servicio de urgencias de un hospital terciario. Se evaluaron variables clínicas (desarrollo de un evento de ETV a tres meses) y bioquímicas (niveles de actividad anti-Xa).  Métodos: se incluyeron aquellos pacientes con patología médica aguda con indicación de tromboprofilaxis según la guía PRETEMED. Se determinó la actividad anti-Xa de cada paciente que cumplió los criterios de inclusión. Se identificaron los casos de ETV sintomática durante el ingreso hospitalario y durante los tres meses posteriores al alta del servicio de urgencias.  Resultados: se incluyeron un total de 100 pacientes. Los factores de riesgo de ETV predisponentes más frecuentes fueron la edad (80 % &gt; 60 años y 66 % &gt; 70 años), neoplasia (28 %), EPOC (28 %) y obesidad (29 %). Los factores de riesgo desencadenantes más frecuentes fueron la presencia de una infección aguda (58 %), inmovilidad (33 %) y quimioterapia (17 %). Según la Guía PRETEMED, se clasificaron como de bajo riesgo (0 %), medio (20 %) y alto (80 %). Durante los tres meses de seguimiento, se observó un 3 % de episodios de ETV sintomáticos (ninguno de estos se produjo durante el ingreso). Un 48 % de los pacientes estaba fuera del rango de actividad anti-Xa tromboprofiláctica. Los factores asociados a esta situación fueron ser mujer y tratamiento con enoxaparina 20 mg al día. No hubo diferencias estadísticamente significativas en la aparición de complicaciones tromboembólicas en relación a los niveles de actividad anti-Xa.  Conclusiones: es necesario estratificar el riesgo de ETV en todos los pacientes, también en aquellos ingresados en unidades de corta estancia, y se abre la necesidad de evaluar las dosis recomendadas de tromboprofilaxis. Observamos una ausencia de correlación entre criterios de eficacia clínica y bioquímica con las pautas habituales de tromboprofilaxis, por lo que resulta cuestionable recomendar su monitorización.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: numerous studies support the use of thromboprophylaxis in patients at risk of thromboembolic disease (VTE) that require hospitalization. There is little evidence in the indications of thromboprophylaxis in the population of acute patients admitted to a Short Stay Unit.  Objectives: to study the use of thromboprophylaxis in patients admitted to a Short Stay Unit of the Emergency Department of a tertiary hospital. Clinical variables (development of a three-month VTE event) and biochemical (anti-Xa activity levels) were evaluated.  Methods: those patients with acute medical pathology with indication of thromboprophylaxis were included according to the PRETEMED guideline. The anti-Xa activity of each patient that met the inclusion criteria was determined. Cases of symptomatic VTE were identified, during hospital admission and later, in the three-month follow-up of the Emergency Department.  Results: a total of 100 patients were included. The most frequent predisposing VTE risk factors were age (80 % &gt; 60 years and 66 % &gt; 70 years), neoplasia (28 %), COPD (28 %) and obesity (29 %). The most frequent risk factors were the presence of an acute infection (58 %), immobility (33 %) and chemotherapy (17 %). According to the PRETEMED Guide, they were classified as low risk (0 %), medium (20 %) and high (80 %). In the 3 months of follow-up, 3 % of symptomatic VTE episodes were observed, none of these occurred during admission. 48 % of the patients were outside the range of anti-Xa thromboprophylactic activity. The factors associated with this situation were being a woman, treatment with enoxaparin 20mg a day and greater weight. There were no statistically significant differences in the occurrence of thromboembolic complications in relation to anti-Xa activity levels.  Conclusions: it is necessary to stratify the risk of VTE in all patients, also in those admitted to short stay units and opens the need to evaluate the recommended thromboprophylaxis doses. We observed an absence of correlation between clinical and biochemical efficacy criteria with the usual thromboprophylaxis guidelines, and it is questionable to recommend their monitoring.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad tromboembólica venosa (ETV)]]></kwd>
<kwd lng="es"><![CDATA[Tromboprofilaxis]]></kwd>
<kwd lng="es"><![CDATA[Heparina de bajo peso molecular (HBPM)]]></kwd>
<kwd lng="es"><![CDATA[Unidad de corta estancia]]></kwd>
<kwd lng="en"><![CDATA[Venous thromboembolic disease (VTE)]]></kwd>
<kwd lng="en"><![CDATA[Thromboprophylaxis]]></kwd>
<kwd lng="en"><![CDATA[Low molecular weight heparin (LMWH)]]></kwd>
<kwd lng="en"><![CDATA[Short stay unit]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Grupo Multidisciplinar para el Estudio de la Enfermedad Tromboembólica en España</collab>
<source><![CDATA[Estudio sobre la enfermedad tromboembólica venosa en España]]></source>
<year>2006</year>
<publisher-name><![CDATA[Sociedad Española de Medicina Interna (SEMI)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldhaber]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[MacDougall]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2000</year>
<volume>118</volume>
<page-range>1680-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldhaber]]></surname>
<given-names><![CDATA[SZ]]></given-names>
</name>
<name>
<surname><![CDATA[Tapson]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2004</year>
<volume>93</volume>
<page-range>259-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geerts]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Heit]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Clagett]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of venous thromboembolism]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2001</year>
<volume>119</volume>
<page-range>132S-75S</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samama]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophilaxys in Medical Patients with Enoxaparin Study Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>341</volume>
<page-range>793-800</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leizorovicz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Turpie]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<collab>PREVENT Medical Thromboprophylaxis Study Group</collab>
<article-title xml:lang=""><![CDATA[Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>110</volume>
<page-range>874-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Gallus]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients:randomized placebo controlled trial]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2006</year>
<volume>332</volume>
<page-range>325-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medrano Ortega FJ]]></surname>
<given-names><![CDATA[Navarro]]></given-names>
</name>
<name>
<surname><![CDATA[Puerto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal Serrano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía PRETEMED 2007 sobre prevención de enfermedad tromboembólica venosa en patología médica]]></source>
<year>2003</year>
<publisher-loc><![CDATA[Córdoba ]]></publisher-loc>
<publisher-name><![CDATA[SADEMI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collignon]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Frydman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Caplain]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>1995</year>
<volume>15</volume>
<page-range>119-23</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samama]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contemporary laboratory monitoring of low molecular weight heparins]]></article-title>
<source><![CDATA[Clin Lab Med]]></source>
<year>1995</year>
<volume>15</volume>
<page-range>119-23</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Warkentin]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Shaughnessy]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2001</year>
<volume>119</volume>
<page-range>64S-94S</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Planes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The relationship between antifactor Xa level and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>1989</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>940-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walenga]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hoppensteadt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fareed]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laboratory monitoring of the clinical effects of low molecular weight heparins]]></article-title>
<source><![CDATA[Thromb Res Suppl]]></source>
<year>1991</year>
<volume>14</volume>
<page-range>49-62</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kovacs]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weir]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[MacKinnon]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Body weight does not predict anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>1998</year>
<volume>91</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>137-42</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schoch]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Buchmann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>1986</year>
<volume>56</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>243-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turpie]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Hirsh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized controlled trial of low-molecular weight heparin (enoxaparin) to prevent deep-vein thromobosis in patients undergoing elective hip surgery]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1986</year>
<volume>315</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>925-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergqvist]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Burmark]]></surname>
<given-names><![CDATA[US]]></given-names>
</name>
<name>
<surname><![CDATA[Frisell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low molecular weight heparin once daily compared with conventional low heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis]]></article-title>
<source><![CDATA[Br J Surg]]></source>
<year>1986</year>
<volume>73</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>204-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Handeland]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[Abildgaard]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Holm]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose adjusted heparin treatment of deep venous thrombosis:a comparison of unfractionated and low molecular weight heparin]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>1990</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>107-12</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bara]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leizorowicz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Picolet]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin (LMWH) or unfractionated heparin]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>1992</year>
<volume>65</volume>
<numero>4-5</numero>
<issue>4-5</issue>
<page-range>641-50</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harenberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Huhle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Piazolo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low molecular-weight heparin]]></article-title>
<source><![CDATA[Semin Thromb Hemost]]></source>
<year>1997</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>167-72</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bara]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Planes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Samama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and d-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>1999</year>
<volume>104</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>230-40</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieuwenhuis]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Albada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Banga]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin]]></article-title>
<source><![CDATA[Blood]]></source>
<year>1991</year>
<volume>78</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2337-43</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Droege]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Besi]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients]]></article-title>
<source><![CDATA[J Trauma Acute Care Surg]]></source>
<year>2014</year>
<volume>76</volume>
<page-range>450-6</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fraklas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Saffle]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enoxaparin dose adjustment is associated with low incidencie of venous thromboembolic events in acute burn patients]]></article-title>
<source><![CDATA[J Trauma]]></source>
<year>2011</year>
<volume>71</volume>
<page-range>1557-61</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cronin]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Godat]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
<name>
<surname><![CDATA[Berndtson]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients]]></article-title>
<source><![CDATA[Burns]]></source>
<year>2019</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>818-24</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Harada]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Barmparas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma]]></article-title>
<source><![CDATA[JAMA Surg]]></source>
<year>2016</year>
<volume>151</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1006-13</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cosmi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Palareti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Old and new heparins]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2012</year>
<volume>129</volume>
<page-range>388-91</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Ferrer]]></surname>
<given-names><![CDATA[Carlos F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bemiparin. Pharmacological Profile]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2010</year>
<volume>70</volume>
<numero>Suppl.2</numero>
<issue>Suppl.2</issue>
<page-range>19-23</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ansell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factor Xa or thrombin:is factor Xa a better target?]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2007</year>
<volume>5</volume>
<numero>Suppl</numero>
<issue>Suppl</issue>
<page-range>60-4</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antonijoan]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Rico]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-González]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers]]></article-title>
<source><![CDATA[Int J Clin Pharacol Ther]]></source>
<year>2009</year>
<volume>47</volume>
<page-range>726-32</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desjardins]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bara]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boutitie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation of Plasma Coagulation Parameters with Thromboprophylaxis, Patients Characteristics, and Outcome in the MEDENOX Study]]></article-title>
<source><![CDATA[Arch Pathol Lab Med]]></source>
<year>2004</year>
<volume>128</volume>
<page-range>519-26</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Champagne]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients]]></article-title>
<source><![CDATA[J Crit Care]]></source>
<year>2011</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>347-51</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
